

INFORMATION DISCLOSURE STATEMENT

|           |   |  |
|-----------|---|--|
| Applicant | : | Carrara et al.   |
| App. No   | : | Unknown  |
| Filed     | : | Herewith   |
| For       | : | TRANSDERMAL<br>PHARMACEUTICAL<br>FORMULATION FOR MINIMIZING<br>SKIN RESIDUES |
| Examiner  | : | Unknown  |
| Art Unit  | : | Unknown  |

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 7 references to be considered by the Examiner. Also enclosed are 6 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed within three months of the filing date, and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 7, 2006

By: 

Marina L. Gordey  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(805) 547-5580

|  |                      |                               |
|--|----------------------|-------------------------------|
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b> | Application No.      | AP9 Rec'd PCT/PTO 07 APR 2006 |
|  | Filing Date          | Herewith                      |
|  | First Named Inventor | Carrara, Dario Norberto R.    |
|  | Art Unit             | Unknown                       |
| (Multiple sheets used when necessary)                    | Examiner             | Unknown                       |
| SHEET 1 OF 1   | Attorney Docket No.  | KLAUS6.001APC                 |

## U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. | Document Number<br>Number - Kind Code (if known)<br>Example: 1,234,567 B1 | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant | Pages, Columns, Lines Where<br>Relevant Passages or Relevant<br>Figures Appear |
|-------------------|----------|---|--------------------------------|-------------------------------|--|
|                   | 1        | 5,580,574   | 12-03-1996                     | Behl et al.                   |  |
|                   |          |   |                                |                               |  |
|                   |          |   |                                |                               |  |
|                   |          |   |                                |                               |  |
|                   |          |   |                                |                               |  |
|                   |          |   |                                |                               |  |
|                   |          |   |                                |                               |  |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. | Foreign Patent Document<br>Country Code-Number-Kind Code<br>Example: JP 1234567 A1 | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant | Pages, Columns, Lines<br>Where Relevant Passages or<br>Relevant Figures Appear | T <sup>1</sup> |
|-------------------|----------|--|--------------------------------|-------------------------------|--|----------------|
|                   | 2        | EP 1 325 752 A2  | 07-09-2003                     | Antares Pharma IPL AG         |  |                |
|                   | 3        | WO 95/29678  | 11-09-1995                     | F. Hoffmann-La Roche AG       |  |                |
|                   |          |  |                                |                               |  |                |
|                   |          |  |                                |                               |  |                |

## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>1</sup> |
|-------------------|----------|---|----------------|
|                   | 4        | LIPP, R. (1998) "Selection and use of crystallization inhibitors for matrix-type transdermal drug-delivery systems containing sex steroids" J. Pharm. Pharmacol. 50:1343-1349.  |                |
|                   | 5        | KOTIYAN, P.N. et al. (2001) "Eudragits: role as crystallization inhibitors in drug-in-adhesive transdermal systems of estradiol" European Journal of Pharmaceutics and Biopharmaceutics 52:173-180.   |                |
|                   | 6        | MOSER, K. et al. (2001) "Passive skin penetration enhancement and its quantification in vitro" European Journal of Pharmaceutics and Biopharmaceutics 52:103-112.   |                |
|                   | 7        | MURA, P. et al. (2000) "Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations" European Journal of Pharmaceutical Sciences 9:365-372.  |                |

2503392  
040506

|  |                 |
|--|-----------------|
| Examiner Signature   | Date Considered |
| <b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.